The prognosis of gliomas is significantly affected by these molecular alterations, such as whether IDH1, IDH2, EGFR, CDKN2A, and CDKN2B are altered for adult‐type gliomas, and whether H3 K27 and H3 G34 are altered for pediatric‐type gliomas [4]. The gene discussed is CDKN2B; the disease is central nervous system cancer.